Navigation Links
Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
Date:9/16/2009

Collaboration with Biomodels facilitates development of novel drug product

BURLINGTON, Mass., Sept. 16 /PRNewswire-USNewswire/ -- Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic for oral mucositis.

Avaxia is developing a polyclonal anti-TNF antibody to be administered to the oral cavity of patients suffering from mucositis. The antibody is designed to reduce the pain and ulceration associated with this serious side effect of cancer treatment. The grant will fund key pre-clinical studies of the antibody in a well-established animal model of radiation-induced oral mucositis.

"We are delighted to have been awarded this grant from the NIH," said Barbara S. Fox, Avaxia's founder and CEO. "Our preliminary data indicate that an anti-TNF antibody, delivered topically to a damaged mucosal membrane, will limit the severity of the inflammatory response induced by ionizing radiation. The support of the NIH provides both the funding we need to advance the development of this much needed therapeutic, and critical scientific validation of our approach."

Avaxia is carrying out the grant-funded research in collaboration with Biomodels LLC, a Watertown-based pre-clinical drug research organization. Biomodels specializes in animal models of toxicities associated with chemotherapy and radiation therapy used for the treatment of cancer and is a world leader in the study of cancer treatment-related mucosal injury (mucositis) .

"We are looking forward to working closely with Avaxia Biologics scientists in developing and testing a drug that could lead to an effective therapy for oral mucositis, a debilitating side effect that impacts virtually every patient who undergoes aggressive cancer treatment," said Edward Fey, managing partner of Biomodels.

Avaxia and Biomodels anticipate extending their productive collaboration to other therapeutic areas, including inflammatory bowel disease and GI enteritis and fibrosis.

ABOUT ORAL MUCOSITIS. Oral mucositis is a serious side effect of cancer chemotherapy and radiation therapy. According to a 2008 report from the National Comprehensive Cancer Network, mucositis has "emerged as the most significant adverse symptom of cancer therapy reported by patients." Mucositis is associated with severe pain and risk of infection, necessitating the use of systemic narcotics and the insertion of a feeding tube to provide nutrition. Most significantly, when mucositis develops, the dose and frequency of cancer treatment is often reduced, leading to a significant decrease in both short-term efficacy and long-term disease-free survival. There are no approved medications for the treatment of mucositis associated with most forms of cancer treatment.

ABOUT AVAXIA BIOLOGICS, INC. Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing orally-delivered antibody therapeutics. The antibodies are designed to treat both diseases of the GI tract and systemic diseases where the disease targets are accessible in the GI tract. Avaxia has a proprietary antibody platform and is developing products for oral mucositis, inflammatory bowel disease, and diabetes and obesity.

ABOUT BIOMODELS LLC. Biomodels (www.biomodels.com), a preclinical drug research organization founded in 1997, develops and conducts predictive translational studies for biotechnology and pharmaceutical companies, particularly in the areas of cancer, cancer supportive care, radiation therapy, and inflammatory diseases.

The company specializes in (non-GLP) efficacy studies that optimize dose, schedule and define mechanism of action. The company also has particular expertise in modeling inflammatory diseases, including those conditions affecting the gastrointestinal tract. Biomodels' studies enable organizations to more readily identify lead compounds, decrease the time to a clinical trial and increase the chance of clinical success. Biomodels is headquartered in Watertown, MA.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ... Exchange: PBT.U), is excited to announce the formation ... on developing preclinical ophthalmology assets through proof of ... anti-inflammatory created by Portage Pharmaceuticals Limited and being ... ocular surface and anterior segment diseases. This agent ...
(Date:11/30/2016)...  Tempus, a technology company focused on supporting ... Cancer Center have partnered to better determine which ... treatment based on next generation genomic and transcriptomic ... research collaboration, Tempus will provide sequencing and analysis ... to Penn. Utilizing next-generation sequencing, machine learning and ...
(Date:11/30/2016)... --  Merck , a leading science and technology company, ... of agreements with Evotec AG, whereby Evotec AG will ... such as CRISPR and shRNA libraries. Combining access to ... pathway to explore and identify new drug targets. ... targets, a process that can be time- and labor-intensive," ...
(Date:11/30/2016)... Park, North Carolina (PRWEB) , ... November 30, 2016 , ... ... approved the names and symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine ... a 5-month period of public review, the names earlier proposed by the discoverers have ...
Breaking Biology Technology:
(Date:11/24/2016)... Nov. 23, 2016 Cercacor today introduced Ember ... their trainers non-invasively measure hemoglobin, Oxygen Content, ... and Respiration Rate in approximately 30 seconds. Smaller than ... and immediate access to key data about their bodies ... training regimen. Hemoglobin carries oxygen to ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/17/2016)... 17, 2016  AIC announces that it has just released a new white paper ... high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or HPC ...
Breaking Biology News(10 mins):